DarbeLus
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in SF3B1 Wild Type Lower-risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 60 patients (estimated)
- Sponsors
- Smilow Cancer Hospital at Yale New Haven
- Collaborators
- Bristol Myers Squibb
- Tags
- Red Blood Cell Stimulant
- Trial Type
- Supportive
- Last Update
- SparkCures ID
- 2163
- NCT Identifier
- NCT07096297
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.